Business Context and Reporting Period
This Form 8-K reports on events occurring on September 4, 2025, regarding Cyclacel Pharmaceuticals, Inc. (the "Company"). The filing details the results of a special meeting of shareholders held virtually to approve critical corporate actions, including a name change to Bio Green Med Solution, Inc. and a significant equity transaction.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders approved three key proposals at the special meeting:
- Proposal 1: Issuance of Shares to Fitters Parent. Approved with 58.8% of votes cast (1,095,988 votes FOR, 6,691 AGAINST, 131 ABSTAIN). This authorizes the issuance of common stock pursuant to an Exchange Agreement.
- Proposal 2: Potential Issuance of >20% Common Stock. Approved with 58.8% of votes cast (1,095,986 votes FOR, 6,664 AGAINST, 160 ABSTAIN). This is required to comply with Nasdaq Listing Rule 5635(a) regarding the Transaction.
- Proposal 3: Corporate Name Change and Charter Amendment. Approved with 58.9% of votes cast (1,097,489 votes FOR, 5,151 AGAINST, 170 ABSTAIN). The Company will change its name to Bio Green Med Solution, Inc.. The amendment also permits stockholder actions by written consent, ratifies prior written consent actions, and opts out of Section 203 of the Delaware General Corporation Law (DGCL) regarding business combinations.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the implications of the approved transactions. The primary contingency noted is the execution of the Exchange Agreement and the subsequent name change.
Investor Verification Checklist
- Verify the terms of the Exchange Agreement with Fitters Parent to understand the dilution impact and consideration received.
- Confirm the effective date of the name change to Bio Green Med Solution, Inc. and the ticker symbol update on the Nasdaq Capital Market.
- Review the definitive proxy statement filed on July 25, 2025, for detailed financial and operational context regarding the Transaction.
- Monitor subsequent filings for the actual issuance of shares and the updated capital structure.